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Abstract
Dihydrofolate reductase (DHFR) is an essential enzyme that plays an important role in
the production of cofactors that are required in deoxyribonucleic acid (DNA) synthesis.
The literature suggests that DHFR is a potential drug target for the elimination of the
parasitic worm, B. malayi. B. malayi is one of the causative parasites of lymphatic
filariasis, a globally neglected tropical disease. In this study, we expressed and purified B.
malayi DHFR. Expression was carried out in E. coli with a His6-tagged construct, and
purification was achieved through affinity chromatography using a special strain of E.
coli cells called “LOBSTR.” The resulting purified and active enzyme was used for
steady-state kinetics characterization and inhibition studies. The catalytic activity, kcaU
was found to be 1.4 ± 0.1s’1, the Michaelis Menten constant, Km, 14.7 ± 3.6pM for
dihydrofolate, and the equilibrium dissociation constant, Kd, 22 ±0.0 lpM. B. malayi
DHFR was compared to 13 other DHFR homologs in terms of ligand specificity
determining residues; L. major, T. cruzi, T. bruci, and T. gondii exhibited the highest
homology. Known inhibitors of these DHFR homologs were assayed with B. malayi
DHFR and an inhibition profile was created for the enzyme. IC50 values were determined
to be 0.0036 ± 0.0008 pM for methotrexate, 109 ± 34 pM for pyrimethamine, 32 ± 22
pM for trimethoprim, 771 ± 4 4

pM for cycloguanil, >20,000 pM for 2,4-

diaminopyrimidine, and 154 ± 46 pM for 2,4-diaminoquinazoline. These results provide
the basis for the development of more potent and less toxic compounds that can inhibit B.
malayi DHFR and help cure lymphatic filariasis.
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1. Introduction
1.1 Disease background
Lymphatic filariasis, also known as elephantiasis, is a neglected disease that
affects more than 120 million people in 80 countries worldwide. This parasitic disease is
caused by the nematodes W. bancrofti, B. timori, and B. malayi\ the latter is the focus of
this research. The disease is transmitted by mosquitos that carry the infective stage
larvae. Once the larvae enter the blood of a human host, they develop into adult female
and male worms located in the lymphatic system. The lymphatic system damage caused
by this parasite is especially detrimental to the infected population because the lymphatic
system is an essential component of the immune system.19

Figure 1 & 2. B. malayi in a blood smear.
Lymphatic filariasis is associated with poverty; there is an ongoing need for more
potent and economic drugs for the elimination of this disease. In 1997 the World Health
Organization declared the disease as “eradicable” and in 2000 a program started with the
purpose to eliminate the disease. This program has as its goals to stop transmission and
control morbidity by administrating the combination of two sets of drugs,

1

diethylcarbamazine citrate (DEC) and albendazole, or ivermectin and albendazole once a
year for at least 5 years in areas prone to the occurrence of the disease. Two
pharmaceutical companies, GlaxoSmithKline and Merck & Co. Inc. pledge to provide
these drugs at no cost for as long as it takes to reach the set goals. Out of the 72 countries
targeted by the program, so far only two countries, the Republic of Korea and China,
have declared elephantiasis as no longer a threat to their population. In general, the
progress seems to be going rather slow, a fact that can be attributed mostly to the
prevalent ongoing need to understand the epidemiology of elimination of lymphatic
filariasis.
1.2 Target overview
NADPH+H+

NADP+

dihydrofolate

tetrahydrofolate

Figure 3. Dihydrofolate is reduced to tetrahydrofolate by the enzyme dihydrofolate
reductase (DHFR). DHFR catalyzes the transfer of a hydride from the cofactor NADPH,
which in turns gets protonated.

Dihydrofolate reductase (DHFR) is a monomeric enzyme of about 20KDa that
has been evolutionarily well conserved. It catalyzes the reaction from dihydrofolate to
tetrahydrofolate in the presence of NADPH. Tetrahydrofolate is a precursor of cofactors
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necessary for the synthesis of purines, pyrimidines, and many amino acids, which are
necessary for cell proliferation and growth.

Figure 4. 3D structure of E. coli DHFR. NADPH is shown in green and DHF is shown in
magenta.

DHFR is a therapeutic target for infectious diseases.15 Antifolates are a specific
group of compounds that inhibit DHFR; the group includes anticancer, antibacterial and
antimalarial drugs. DHFR inhibition by these antifolate compounds is mediated through
the disruption of DNA biosynthesis and it is the basis of chemotherapeutic action.7 The
evaluation of synthetic antifolate agents, biguanide and dihydrotriazine, along with the
drugs pyrimethamine and trimethoprim, has demonstrated that DHFR inhibitors could be
promising molecules for the treatment of B. malayi? Furthermore, the evaluation of 12
diverse antifolate compounds with 2,4-diaminopyrimidine and 2,4-diamino-s-triazine
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structural features against B. malayi proves that DHFR inhibitors are indeed novel drug
candidates against lymphatic filariasis.16 However, these studies were done on B. malayi,
not on the target; the purified RraDHFR. Encouragement came from these findings to
purify 5mDHFR and prove that the target can be inhibited with antifolate compounds, as
predicted.
1.3 Project goals
1.3.1 Previous work (by Karla Sanchez)
The first goal of this project was to express and purify B. malayi DHFR for the
first time. Before I joined this project, graduate student Karla Sanchez obtained the amino
acid sequence of 5mDHFR from UniProt (A8QGA9) and engineered a His6-tag at the Nterminus. The purpose of the His6-tag is to enable the capture of the protein by nickel or
cobalt ions on the specific resin used for purification.1The designed DNA-sequence was
then codon optimized for expression in E. coli (Genewiz) and the resulting 5raDHFR
DNA fragment was subcloned into the pET25b expression vector. At this point the
project ran into some difficulties when Z?mDHFR did not exhibit any catalytic activity.
Dr. Goodey, Dr. Gubler, and Karla worked hard to fix this issue, and they realized that
the problem came from the amino acid sequence of the enzyme. There are two different
fimDHFR sequences on UniProt, one of them (A8QGA9) was entered on August 2014
and was missing 13 amino acids (residues 113-125) essential for the folding of the
protein; which will be referred to as the loop mutant or Ain.^RmDHFR from hereon.
After the right sequence was obtained from UnitProt (A8QBG1, entered on March 2015),
the same process previously explained was carried out on the full sequence and Z?raDHFR
exhibited catalytic activity.
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Figure 5. Ni-NTA resin interacting with polyhistidine tag.
1.3.2 My goals
Once I joined this project, the first challenge was to purify B. malayi DHFR,
which had been expressed in BL21 (DE3) E. coli cells. The subsequent affinity
chromatography purification yielded impure protein (<95%). It was speculated that the
impurity most likely represented (a) contaminating histidine-rich E. coli protein(s) when
using Ni-NTA affinity chromatography. Dr. Ueli Gubler suggested to introduce our
pET25n-RraDHFR plasmid into a recently described special E. coli expression strain,
BL21 (DE3) derivative, called “LOBSTR” (low background strain). The LOBSTR strain
is specifically engineered to eliminate the most abundant contaminants caused by Hismediated purification.1The approach works by lowering the background contamination
due to ArnA (74 KDa) and SlyD (21 KDa), bifunctional enzymes involved in the
modification of lipid A phosphates with aminoarabinose and a peptidyl-prolyl cis/transisomerase, respectively.1When recombinant protein expression is low, the protein starts
competing with endogeneous ArnA and SlyD for binding to the Ni or Co resin, leading to
the co-purification of ArnA and SlyD as impurities. The LOBSTR strain genomically
modifies ArnA and SlyD by mutagenizing them to change the surface-expose His to Ser.
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These modifications reduce the Ni and Co binding affinity of the unwanted host
proteins.1
Kinetic characterization and enzyme inhibition studies followed the expression
and purification of RraDHFR. Kinetic parameters like Km and kcat serve as a comparison
between different DHFRs from different organisms. The dissociation constant KDserves
as a comparison between the loop mutant and the wildtype in terms of the binding of the
cofactor NADPH and the consequent folding of the protein. RraDHFR is expected to bind
with a greater affinity than An3_i25#raDHFR.
In order to complete an inhibition profile for the enzyme, it was necessary to
make predictions of antifolate compounds that could potentially inhibit Z?raDHFR. A
novel phylogenetics-based method for predicting residues involved in inhibitor
specificity in the DHFR family identified eighteen amino acid positions in thirteen DHFR
homologs that are involved in ligand specificity (inhibitor binding).5 With this
information at hand, and by extensive alignments of the 13 DHFR homologs with B.
malayi DHFR, the 18 amino acid positions predicted to be involved in inhibitor
specificity were determined in the BmDHFR sequence. The DHFR homologs with the
highest percentage identity to the 18 amino acid residues in BmDHFR were L. major, T.
cruzi, T. gondii, and T. bruci. Known DHFR inhibitors of these organisms were predicted
to also inhibit our enzyme and were obtained to generate an inhibition profile for B.
malayi DHFR.
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2. Methods and Materials
2.1. BmDHFR expression
BL21(DE3) or LOBSTR (Kerafast) cells were transformed with isolated pET25bRraDHFR DNA and expression of RmDHFR was explored at room temperature and 30
°C. BL21(DE3) and LOBSTR transformants were grown in LB/amp (lOOug/ml
ampicillin) to an OD600 ~0.6 at 37 °C. Cultures were allowed to reach the desired
expression temperatures and expression was induced with 0.3 mM IPTG. Cells were
harvested after 5 hours and overnight. To extract soluble protein, cells were harvested by
centrifugation at 5,000 rpm for 30 min, resuspended in ~15 mL of Equilibration Buffer
(20 mM sodium phosphate, 300 mM NaCl (PBS), 10 mM imidazole, pH 7.4) and lysed
by sonication for 4 min (output: 5, duty cycle: 10, W-225 Heat Systems Ultrasonics
sonicator with microtip). Cell debris and soluble protein extract were separated by
centrifugation at 5,000 rpm for 30 minutes (Beckman Coulter Avanti J-26S XP centrifuge
with JA-10 rotor).

2.2. Purification of BmDHFR
Soluble cell lysate was loaded onto HisPur™ Ni-NTA Resin (Thermo Scientific)
equilibrated in a gravity-flow column with Equilibration Buffer (20 mM sodium
phosphate, 300 mM NaCl (PBS), 10 mM imidazole, pH 7.4). The resin was washed with
Wash Buffer (PBS, 25 mM imidazole, pH 7.4) and RmDHFR was eluted with Elution
Buffer (PBS, 250 mM imidazole, pH 7.4). Wash and elution fractions were monitored for
protein content by a microtiter-plate based Bradford assay.
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2.3. BmDHFR activity assay
ÆraDHFR activity was determined with saturating concentrations of NADPH and
DHF (100 |iM each) by measuring the change in absorbance at 340 nm. The differential
extinction coefficient value of 13.2 mM 'em 1 (for the combination of conversion of
NADPH to NADP+ and DHF to THF) was used to convert the change in absorbance over
time to an initial velocity. In a typical experiment, (reaction volume of 200 pi) RmDHFR
(45 to 85 nM) was incubated with NADPH (100 pM) for 2-3 min, adding DHF to a final
concentration of 100 pM, and recording the absorbance at 340 nm for 3 minutes. All
experiments were carried out in MTEN buffer (50 mM 2-morpholinoethane sulphonic
acid (MES), 25 mM Tris, 25 mM ethanolamine, and 100 mM NaCl). The assays were
completed in triplicate at 25 °C in a SpectraMax M3 microplate reader. The optimum pH
for the DHFR reaction was determined by comparing the rate of change in absorbance at
pH values ranging from 4 to 10 in one unit increments. Turnover number (&cat) was
y

calculated using the formula /cca^ = max at pH 6.00.

2.4. Determination of the Michaelis-Menten constant (KM)
The affinity of RraDHFR for its substrate DHF was determined by measuring the
enzyme activity as a function of increasing concentrations of DHF. The concentration of
DHF in the well ranged from 0.13 to 100 pM; dilutions were made in MTEN pH 6.0.
NADPH (100 pM) and 46 nM enzyme were incubated for 2-3 min, DHF was added to
initiate the reaction, and absorbance was recorded at 340 nm. As above, all experiments
were completed at 25 °C in MTEN at pH 6.0 in a reaction volume of 200 pi. Initial
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velocity was plotted as a function of DHF concentration using Kaleidagraph and the data
was fitted to the Michaelis-Menten equation. Assays were completed in triplicate.

2.5. Prediction of BmDHFR Inhibitors
Previous research predicted that 18 amino acid positions in 13 selected DHFR
homologs would play a role in enzyme in inhibition.5 The 18 residues were identified in
RmDHFR by aligning its entire sequence with the sequences of the 13 homologues in
MEGA software. The unwanted amino acid residues were deleted from each of the 14
sequences using MEGA software, leaving the sequences with only the desired 18 amino
acid positions. An individual alignment was done between the 18 residues of Bm and
each of the 13 homologs; the percent alignment identity was recorded. A literature search
was conducted with the top 4 homologous DHFR proteins having the highest percent
identity to Bm DHFR. The drugs that inhibit those 4 homologs were predicted to also
inhibit Bm DHFR and were subsequently used for inhibition studies.

2.6. Effects of DMSO concentration on RraDHFR activity.
Stock solutions of predicted RraDHFR inhibitors were prepared in DMSO.
Control experiments with DMSO were conducted to confirm that DMSO at the relevant
concentrations did not affect 5mDHFR activity. The assay was set up the same way, with
concentrations of 100 pM and 46 nM for NADPH and Z?raDHFR respectively. 15 ul
DMSO stocks resulting in concentrations ranging from 18% to 75% were included in the
assay as replacement for the inhibitors. The final concentration of DMSO in the
inhibitions assays was always below 3 % in all experiments meaning the activity of
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RraDHFR was not be affected by the inclusion of DMSO; DMSO did not inhibit
RmDHFR.

2.7. Inhibition Studies
Methotrexate (MTX, Sigma M9929), pyrimethamine (PMT, Fluka 46706), 2,4diaminopyrimidine (Sigma 468231), 2,4-diaminoquinazoline (Sigma CDS001152),
trimethoprim (TMP, MP Biomedicals 0910013), and cycloguanil (CYC, Cayman 16861)
were evaluated as inhibitors of RraDHFR catalytic activity. Stock solutions were prepared
in DMSO and dilutions of all stock solutions were made in MTEN pH 6.0. RraDHFR
activity was measured as described above, with varying concentrations of inhibitor
added. NADPH (100 pM) and 5raDHFR (46 nM) in a total volume of 200 pi were
incubated with 15 pi inhibitor (varying concentrations in different wells) for 2-3 minutes
before the reaction was initiated by adding DHF (final concentration 20 pM, final
reaction volume 200 ul). Percent activity for each inhibitor concentration was obtained by
dividing the rate from the inhibition experiment by the rate of the control experiment
where no inhibitor was added. Dose response curves were generated in Kaleidagraph.
Data was fitted to the Hill equation.
% response = min response + (max response - min resp onse)/^ +
with n = -1. IC50 values for each inhibitor were calculated. All assays were completed in
triplicate.
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2.8. Determination of equilibrium dissociation constant
The thermodynamic dissociation constant (KD) for the binding of NADPH to
5mDHFR and An3_i255mDHFR was determined by monitoring the tryptophan
fluorescence (ex. 290 nm/em. 340 nm) as NADPH was added to 228 nM enzyme
(wildtype) and 172 nM (An3.i25#mDHFR) in MTEN, pH 6.0 at room temperature. The
NADPH concentration ranged from 0 to 1.4 mM.

3. Results and Discussion
3.1. Expression and purification of recombinant #mDHFR
Based on the UniProt database amino acid sequence A8G6A9, the DNA sequence
coding for RmDHFR was designed to incorporate an N-terminal His6-tag. The sequence
was codon optimized for expression in E. coli (Genewiz) and the resulting 5raDHFR
DNA fragment was subcloned into the pET25b expression vector. This pET25bRraDHFR plasmid was introduced into the BL21(DE3) derivative, “LOBSTR”.1 Several
small-scale expression studies revealed that soluble RmDHFR protein expression could
be obtained by induction with 0.3 mM IPTG at room temperature for 24 hours.
For larger scale purification, soluble protein was derived from an induced 250 mL
culture by sonication and centrifugation, and the resulting supernatant was applied to a
standard Ni-NTA affinity column. Purification of the soluble, recombinant RraDHFR can
be completed through this single step if expression is performed in the “LOBSTR”
expression strain. SDS-PAGE analysis of the eluate showed that the enzyme had the
expected size of approximately 22 kDa, consistent with the predicted molecular weight of
22.086 kDa calculated from the DNA sequence (Figure 7). Expression and purification
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via this method yielded ~1.8 mg purified 5mDHFR/L of induced culture. Concentration
of RraDHFR was 46 nM. However, when expression was carried out in the standard
BL21(DE3) strain, followed by Ni-NTA chromatography of soluble protein, a -66 kDa
contaminant remained in the eluted protein fractions (Figure 6).

Figure 6. SDS-PAGE analysis of 5raDHFR expression and purification in the BL21
(DE3) E. coli expression strain. The Ni-NTA column one step purification resulted in
<95% pure protein due to the histidine-rich host proteins that were co-purified. Lane 1.
Ladder (Fisher Bioreagents EZ-Run Protein Standard BP3600); Lane 2. Flow-through;
Lane 3. Wash; Lanes 4-8. Elution fractions from the Ni-NTA column.
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Flowthrough

Wash
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Elution

Figure 7. SDS-PAGE analysis of Z?mDHFR expression and purification in the LOBSTR
E. coli expression strain. The Ni-NTA column one step purification resulted in >95 %
pure protein. Lane 1. Ladder (Fisher Bioreagents EZ-Run Protein Standard BP3600);
Lane 2. Flow-through; Lane 3. Wash; Lanes 4-7. Four separate elution (1 mL each)
fractions from the Ni-NTA column.

3.2. BmDHFR activity assay
After the expression and purification of BmDHFR, the next step was the make
sure the enzyme had catalytic activity. This was tested on a 96-well plate reader using
different concentrations of enzyme until there was an evident decrease in absorbance, i.e.
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a slope in the plot of absorbance vs. time at a wavelength of 340nm. The concentrations
of DHF and NADPH were 100 pM each and RraDHFR was 46 nM.
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Figure 8. 5raDHFR catalytic activity with saturating concentrations of NADPH and DHF
(100 pM each) and concentration of RraDHFR of 46 nM. Change in absorbance was
measure at 340nm over 10 minutes. The differential extinction coefficient value of 13.2
mM 'cm'1(for the combination of conversion of NADPH to NADP+ and DHF to THF)
was used to convert the change in absorbance over time to an initial velocity.
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3.3. Kinetic Characterization of BmDHFR
The dependence of the catalytic activity on pH was explored; catalytic activity was found
to be highest at pH ~ 6.0 (Figure 10). The &cat value for RraDHFR was determined at pH
6.0 to be 1.4 ± 0.1s'1 (Figure 9) and the

for DHF 14.7 ± 3.6 pM (Figure 11).

y = -0.0008x+0.8208

Figure 9. A representative graph of three trials of kca{ measurements at a wavelength of
340nm. This experiment was carried out in a spectrophotometer using a 1 mL plastic
cuvette as oppose to the other experiments that were conducted in a 96-well plate
spectrophometer. The enzyme concentration in the assay was 78.6 nM. The average of
the three individual trials gave a kcal of 1.4 ± 0.1s'1.

Sample of calculation of kca{:
AC

time

slope
£Xl

0.0008
(13.2mM ^cm 1)(lc?n)(s)

15

0.0000606mMs 1

Kcat =

0.0000606mMs 1
0.0000393mM

1.542s 1

pH
Figure 10. Dependence of catalytic activity of BmDHFR on pH. Individual experiments
were conducted in a 96-well plate at room temperature with 100 pM NAPDH, 100 pM
DHF and 46 nM BmDHFR. The buffer used was MTEN (1250mM MES, 125mM Tris,
125mM ethanolamine, 500mM NaCl) with pH ranging from 5.5 to 12. The reported data
is an average of duplicate measurements.
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60

Figure 11. Steady-state kinetic analysis of BmDHFR gives a KM value for DHF of 14.7 ±
3.6 pM and a Vmax value of 57 ± 14 nM*s_1 (n=3). The data shown is representative for
one out three experiments. Rate of change of absorbance at 340 nm was measured as a
function of DHF concentration with 100 pM NADPH and 0.045 pM BmDHFR at pH 6.0
at room temperature. Michaelis-Menten curves were generated in KaleidaGraph and
-l
report initial velocity (mM*s ) versus [DHF] (pM).

3.4. Prediction of inhibitor profile against BmDHFR using PAn Predictor
We used a variation of the previously published computational approach (“PAn
Predictor”) to predict antifolate compounds that might serve as effective inhibitors of
B/nDHFR.5 First, we aligned the 13 DHFR homolog sequences used originally to predict
inhibitor specificity determinants in the DHFR family with BmDHFR and identified the
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18 residues in RraDHFR corresponding to the 18 amino acid positions that are inhibitor
specificity determinants in the DHFR family.5 These positions in RmDHFR are Val5,
Glyl2, Met27, Asn44, Ala45, Lys51, Phe60, Val84, Phe89 Leu95, Leu96, Glyl33,
Alal37, Vall39, Phel40, Phel41 and Glul69 (Figure 12). The RraDHFR residue
corresponding to the putative catalytic acid (Asp 27) in E. coli DHFR is Glu26 (indicated
by # in Figure 12). The requirement for the Glu26 to be in the protonated state may
correspond with the sharp decrease in activity as the pH increases shown in Figure 10.
*

BmDHFR
HsDHFR
EcDHFR

*

**

....MNLIVA VDGCGGIGRN GGMPW.FLPA EMARFAKLTT LTMDSGKKNA 45
MVGSLNCIVA VSQNMGIGKN GDLPWPPLRN EFRYFQRMTT TSSVEGKQNL 50
...MISLIAA LAVDRVIGME NAMPW.NLPA DLAWFKRNTL
NKP 39
*

*

*

BmDHFR VIMGRKVWES IPPKFRPLKN
HsDHFR VIMGKKTWFS IPEKNRPLKG
EcDHFR VIMGRHTWES I...GRPXPG

*

*

RFNWLSRKI KEESNENWV ARSFESAISL 95
RINLVLSREL KEPPQGAHFL SRSLDDALKL 100
RKNIILSSQ. .PGTDDRVTW VKSVDEAIAA 84

*
BmDHFR LQDME... NI ETIWNIGGRE VYELGLNSPF LHQMYITRVE
HsDHFR TEQPELANKV DMVWIVGGSS VYKEAMNHPG HLKLFVTRIM
EcDHFR A G ..... DV PEIMVIGGGR VYEQFL..PK AQKLYLTHID

★ ★ ★ ★ ★ ★
GDFLADVFFP 142
QDFESDTFFP 160
AEVEGDTHFP 126

*

BmDHFR EVDYGRFI.K STES....EE MHEEKGIKYR YEIYTVKIDK VA 179
HsDHFR EIDLEKYK.L LPEYPGVLSD VQEEKGIKYK FEVY....EK ND 187
EcDHFR DYEPDDWESV FSEF....HD ADAQNSHSYS FEIL....ER R. 159

Figure 12. Alignment of ÆraDHFR sequence with H. sapiens and E. coli DHFRs. The 18
amino acid positions that are predicted as inhibitor specificity determinants in the DHFR
family are identified by bold letters. These 18 residues were identified in H. sapiens and
E. coli DHFRs by previously published approach PAn Predictor, and in RraDHFR by an
alignment with the 13 DHFR homologs, including Hs and Ec.5 The catalytic residue
Asp27 is labeled on the E. coli sequence (#) and the corresponding Glul7 is labeled on
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the B. malayi sequence (|). (Howell et al. 1986) The horizontal rectangle is showing the
loop mutant on the B. malayi sequence.

We then determined the percentage identity between RmDHFR and other DHFR
sequences based on only these 18 specificity determining residues. This analysis showed
that DHFR sequences from L. major and T. cruzi had the highest homologies (>70%) to
RraDHFR (Table 1).

Entry
P07382
Q27793
Q27783
Q07422
P16184
002604
P13922
P00374
Q920D2
P9WNX1
P0ABQ4
030463
P00381

Organism
Lm
Tc
Tb
Tg
Pc
Pv
pf
Hs
Rn
Mt
Ec
Ma
Lc

Set 1
72.2%
72.2%
66.6%
66.6%
61.1%
50.0%
50.0%
44.4%
44.4%
16.6%
11.1%
11.1%
5.5%

Set 2
72.2%
61.1%
55.5%
55.5%
61.1%
50.0%
44.4%
50.0%
50.0%
16.6%
22.2%
11.1%
16.6%

Set 3
66.6%
61.1%
55.5%
55.5%
55.5%
44.4%
44.4%
44.4%
44.4%
11.1%
11.1%
11.1%
5.5%

Table 1. Highest to lowest percentage identity of 13 organisms to RraDHFR. Sets 1, 2,
and 3 consist of 15, 15, and 12 amino acid positions, respectively.5 In every set, each
DHFR homolog sequence was aligned with 5raDHFR and the percentage identity was
determined. At the top of the list is the organism, L. major DHFR, which was the most
similar to RraDHFR based on the 18 specificity-determining residues. The inhibitors were
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then selected based on this information and by doing a literature search of the drugs that
inhibit the top 4 organisms with the highest percent identity to RraDHFR.

A subsequent literature search and examination of BindingDB (Liu, T 2007)
allowed us to identify a set of six known DHFR inhibitors that inhibit DHFRs with high
homology to ÆmDHFR in terms of the 18 residues studied. The IC50 values of these six
compounds against RraDHFR were determined.

Ki (uM)

Ki
reference
article

0.25

Gilbert,
2002

-16.5

0.12

Gilbert,
2002

White, et al.
2004

L. m a jo r

0.011

5.8uM

Gilbert,
2002

Basco, et al.
1994

T. cru zi

-0.0083

3.8X10'5

Gilbert,
2002

White, et al.
2004

Drugs

Inhibition
Activity

DHFR
homolog

Pyrimethamine

weak

L. m a jo r

Trimethoprim

weak

L. m a jo r

Cycloguanil

weak

Methotrexate

IC50
(uM)

potent
L .m ajor/T.
gon dii/T .

IC50
reference
article

2,4Diaminopyrimidine

potent

cru zi

0.2

0.0078

Pez, et al.
2003

Pez, et al.
2003

2,4Diaminoquinazoline

potent

L. m a jo r

0.2

0.0070

Khabnadide
h, et al. 2005

Khabnadide
h, et al. 2005

Table 2. Known drugs that bind the DHFR homolog sequences with the highest
percentage identity to BmDUFR. The drugs exhibiting potent inhibition activity, low
IC50’s and Ki’s were selected to be acquired for further studies.
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3.5. Effects of DMSO concentration on 5raDHFR activity.
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Figure 13. Z?mDHFR activity at concentrations of DMSO ranging from 18% to 75%
(stock) and 1.4% to 5.6% (in assay). Graph shows that the enzyme retained its catalytic
activity when assayed in various concentrations of DMSO instead of the inhibitor,
proving that DMSO does not alter the inhibition studies results. Individual experiments
were conducted in a 96-well plate at room temperature with conditions in the well of 100
pM NAPDH, 100 pM DHF and 46 nM RmDHFR. Percent activity was obtained by
calculating the slope of the line (abs. at different cone, of DMSO vs. time) over the slope
of the line (abs. with no DMSO vs. time) times 100%.
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3.6. Inhibition by antifolate compounds
Determination of IC50 values of six antifolate compounds against recombinant
RmDHFR showed that methotrexate was the most potent inhibitor of the six compounds
tested against BmDHFR with an IC50 value of 4.0 ± 0.8 nM (Table 3). Pyrimethamine,
trimethoprim, cycloguanil, and 2,4-diaminoquinazoline were found to inhibit RraDHFR
with IC50 values of 109 ± 34, 32 ± 22, 771± 44 and 154 ± 46 pM, respectively (Tables 47). The inhibitor 2,4-diaminopyrimidine did not inhibit RraDHFR at concentrations below
20 mM.

3.6.1. Methotrexate
Inhibition curve, IC50 and Ki determination:

Concentration (nM)
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Figure 14. A representative graph of a B. malayi DHFR inhibition curve in the presence
of the inhibitor Methotrexate. The average of three trials gave an IC50 of 0.0040 ±
0.0008pM. Individual experiments were conducted in a 96-well plate at room
temperature with conditions in the well of 100 pM NAPDH, 100 pM DHF and 46 nM
fimDHFR. Percent activity in the y-axis was determined by dividing the slope of the abs.
of methotrexate at different concentrations vs. time over the slope of the assay (abs. vs.
time) with no inhibitor, and multiplying by 100%.
MTX

IC50 (pM)

Ki (pM)

Trial 1

0.0032998

0.001397898

Trial 2

0.0030152

0.001277333

Trial 3

0.0045142

0.001912356

Average

0.003609733

0.001529195

Std. dev.

0.000796112

0.000337258

Average ± Std. dev.

0.004 ± 0.0008

0.002 ± 0.0003

Table 3. IC50 and Ki from three trials of Methotrexate.
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3.6.2. Pyrimethamine
Inhibition curve, IC50 and K] determination:

Concentration (microM)

Figure 15. A representative graph of one of three separate trials of a B. malayi DHFR
inhibition experiment carried out in the presence of the inhibitor Pyrimethamine. Data fit
using KaleidaGraph. Individual experiments were conducted in a 96-well plate at room
temperature with conditions in the well of 100 pM NAPDH, 100 pM DHF and 46 nM
Z?raDHFR. The average of the three trials gave an IC50 of 90.2 ± 7.9pM. Percent activity
in the y-axis was determined by dividing the slope of the abs. of pyrimethamine at
different concentrations vs. time over the slope of the assay (abs. vs. time) with no
inhibitor, and multiplying by 100%.
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PMT

IC50 (]iM)

K, (|iM)

Trial 1

98.354

41.66581556

Trial 2

82.497

34.94829683

Trial 3

147.38

62.43475504

Average

109.4103333

46.34962248

Std. dev.

33.82503219

14.3293364

Average ± Std. dev.

109 ± 34

46 ± 14

Table 4. IC50 and Ki from three trials of Pyrimethamine.
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3.6.3. Trimethoprim
Inhibition curve, IC50 and K] determination:

Concentration (uM)

Figure 16. A representative graph of a B. malayi DHFR inhibition curve established in
the presence of the inhibitor Trimethoprim. Data fit using KaleidaGraph. The average of
three trials gave an IC50 of 31.8 ± 5.4pM. Individual experiments were conducted in a
96-well plate at room temperature with conditions in the well of 100 pM NAPDH, 100
pM DHF and 46 nM RraDHFR. Percent activity in the y-axis was determined by dividing
the slope of the abs. of trimethoprim at different concentrations vs. time over the slope of
the assay (abs. vs. time) with no inhibitor, and multiplying by 100%.
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TM P

IC 50 OiM)

K i(n M )

Trial 1

15.44

6.541

Trial 2

22.65

9.595

Trial 3

57.32

24.28

Average

31.80333333

13.472

Std. dev.

22.39020396

9.483742774

Average ± Std. dev.

32 ±22

13 ± 9

Table 5. IC50 and Ki from three trials of Trimethoprim.
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3.6.4. Cycloguanil
Inhibition curve, IC50 and Ki determination:

Concentration (uM)

Figure 17. A representative graph of a B. malayi DHFR inhibition curve established in
the presence of the inhibitor Cycloguanil. Data fit using KaleidaGraph. The average of
three trials gave an IC50 of 770.6 ± 534pM. Individual experiments were conducted in a
96-well plate at room temperature with conditions in the well of 100 pM NAPDH, 100
pM DHF and 46 nM 5mDHFR. Percent activity in the y-axis was determined by dividing
the slope of the abs. of cycloguanil at different concentrations vs. time over the slope of
the assay (abs. vs. time) with no inhibitor, and multiplying by 100%.
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CYC

IC50 (nM)

Ki OiM)

Trial 1

719.44

428.1687449

Trial 2

796.99

474.3219838

Trial 3

795.42

473.3876113

Average

770.6166667

458.6261134

Std. dev.

44.32724482

26.38099186

Average ± Std. dev.

771 ±44

459 ± 26

Table 6. IC50 and Ki from three trials of Cycloguanil.
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3.6.5. 2,4-Diaminoquinazoline
Inhibition curve, IC50 and Ki determination:

Concentration (mM)

Figure 18. A representative graph of a B. malayi DHFR inhibition curve established in
the presence of the inhibitor 2,4-Diaminoquinazoline. Data fit using KaleidaGraph. The
average of three trials gave an IC50 of 192.9 ± 88.0pM. Individual experiments were
conducted in a 96-well plate at room temperature with conditions in the well of 100 pM
NAPDH, 100 pM DHF and 46 nM 5mDHFR. Percent activity in the y-axis was
determined by dividing the slope of the abs. of 2,4-diaminoquinazoline at different
concentrations vs. time over the slope of the assay (abs. vs. time) with no inhibitor, and
multiplying by 100%.
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2,4-Diaminoquinazoline

IC50 (pM)

Ki (pM)

Trial 1

137.89

58.41449568

Trial 2

117.72

49.86985591

Trial 3

205.66

87.12397695

Average

153.7566667

65.13610951

Std. dev.

46.06706235

19.5154414

Average ± Std. dev.

154 ±46

65 ±20

Table 7. IC50 and Ki from three trials of Cycloguanil.

3.7. Comparing experimental IC50 values in Table 8 for B. malayi DHFR to predictions

Compound

IC50(hM)

Ki(pM)

Methotrexate

0.004 ± 0.0008

0.002 ± 0.0003

Pyrimethamine

109 ±34

46 ± 14

Trimethoprim

32 ±22

13 ±9

Cycloguanil

771 ±44

459 ± 26

2,4-Diaminopyrimidine

>20,000

>8,472

2,4-Diaminoquinazoline

154 ±46

65 ±20

Table 8. Summary of IC50 and Kj values for a set of antifolate compounds tested against
RraDHFR. Values are averages of at least triplicate experiments and standard deviations
are shown. The experiments were conducted at pH 6.0, at room temperature, with 100
pM NADPH, 100 pM DHF, and 46 nM DHFR. The Kj values were obtained using the
Cheng Prusoff equation (Prusoff 1973).
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The predicted inhibitors’ IC50 values from the literature are given in Table 1; they
represent the values obtained for the DHFR homologs most similar to B. malayi DHFR in
terms of the amino acid positions predicted to play a role in enzyme inhibition.5 A
comparison of the experimental to the expected values showed that the IC50’s for
methotrexate and trimethoprim were closest to the predictions. Methotrexate was
confirmed to be the strongest inhibitor for B. malayi DHFR, this did not surprise because
based on its close homology to L. major DHFR. However, IC50 values for other
inhibitors like cycloguanil, pyrimethamine, and 2,4-diaminoquinazoline were not close to
the predictions; they are considered weak inhibitors. They were expected to be better
inhibitors based on the prediction from Table 1 showing that these compounds inhibit L.
major with more potency. Notably, 2,4-diaminopyrimidine was determined not to be an
inhibitor of B. malayi DHFR, despite the predictions and its similarity to 2,4diaminoquinazoline. These findings suggest that perhaps a compound with a higher
resemblance to the structure of 2,4-diaminoquinazoline could be a possible inhibitor for
B. malayi DHFR. The extra ring in the 2,4-diaminoquinazoline structure could play a role
in the inhibition of the DHFR enzyme. In conclusion, with varying potencies all
compounds except for 2,4-diaminopyrimidine inhibited Z?mDHFR, as it was expected.
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3.8. Dissociation Constants for NADPH of Mutant and Wildtype B. malayi DHFR

1 106

[NADPH] (mM)

Figure 18. Dissociation constant

( K d)

analysis of NADPH in the presence of the mutant

(A) and wildtype (B) of B. malayi DHFR. Both graphs above are representative of three
separate trials. Concentration of enzyme and NAPDH were ~200nM and 0 to 1.4 mM,
respectively. The wavelength was at 340nm. The average for the mutant KDwas 129 ± 38
pM and the average for the wildtype KDwas 22 ±14 pM.

Based on the KD data we can conclude that An3.i255wDHFR binds NADPH with
a lower affinity than BtiiDHFR. However, these findings suggest that the mutant enzyme
is still able to fold to some extent. It can also be concluded that the 13 amino acids
missing from the mutant enzyme are located on the pF-pG loop, by comparison with E.
coli DHFR. In E. coli DHFR this loop plays a role in dynamics associated with catalysis,
therefore we suggest that the pF~pG loop also plays the same role in RwDHFR.
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4. Summary
In summary, I expressed and purified the target enzyme, DHFR, in the B. malayi
organism using a special strain of E. coli cells, LOBSTR, and an Ni-NTA affinity
chromatography. The enzymatic characterization of B. malayi DHFR was carried out
using the purified protein. The Michaelis-Menten constant, Km, was found to be 14.7 ±
3.6pM, which shows that the enzyme has high affinity for the substrate. The turnover
number, kcaU and the equilibrium dissociation constant, KD, for NADPH was found to be
1.4 ± 0.1s'1 and 22 ±0.0 lpM, respectively. The inhibition studies showed that
methotrexate was the strongest inhibitor. However, methotrexate is used for
chemotherapy and is an immunosuppressant, a fact that makes it unsuitable for the
treatment of lymphatic filariasis in human patients. Trimethoprim ranks second after
methotrexate in IC50 and Ki value, suggesting that perhaps it can be a lead compound in
the search for a more potent and less toxic drug. Obtaining the crystal structure of
BmDHFR in the presence and absence of a high affinity inhibitor is the obvious next step
to be undertaken, in order for organic chemists to have a good understanding of the
binding site of the enzyme and be able to work on optimizing existing compounds to fit
in the active site while keeping toxicity and side effects to a minimum. The present
project thus might serve as the basis for the discovery of a potent compound that will
hopefully make it to the market to help cure this neglected disease that affects millions of
unprivileged people.
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